{"name":"Entrada Therapeutics, Inc.","slug":"entrada-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNaGNCZXUxWERHZXhLYVMxOFBMa2MzcE10dXRCeUpfMTZwcEJOYzZ5ZWdtVGRwcVpRU1Y1cUNnY0tFWmFVZXY2VldwQjctSWVnUjF2N08wN21YZVdCNFFNamRRVGFydEFUT0dKN3BCWlE2RnBaSHphZ0RTaFNpWHlWYmZpblM3WmxkZFVNNlF5R0dPMTk5SFkwZE94ZVNjTHp4alhXQ0dvaDZrU21NTTZYOFp3amdzMV9wYWhLamNHMHBGQ2p4bmNWdUFESWNTcVlMZURuVTNOS3FLQm4wQ2xlbEFwU3pjRWEydWpKSERjUGFYX1gwY1RONmFIaGJ0eDZ2ZVItVnRzRXhDZDdOU1JDM1JaRjNJX1ZJcms0LUtwOWo?oc=5","date":"2026-04-07","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Viridian Therapeutics (VRDN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPUFBZVjZTc0VhN29yX3ZtUGRQcDN6X0FOOEF4eTl0TFFlaTlIMVhMc2NrWmFNaHktbnpyd0pPU0ppSHZyZEM0YjFfcTI3TnhOOGFuaE93dnhERGxVWnIwNEhSbG4yZHYzemxzTzJRQ0lIZ3FKV0UzaVFRR3RoVVJJaHM3MS1UQzhsRnJuRUM2UmtOZXVNRUM5OWx1N2F3OEZndVU1ZjIzelNTODEzd1EtU3gweXRuX0IwUlNxVFBpVklFYXlYUWVFclZabXE1c1lGZXVPTGZZeTVFbE9pekxHZ1VVZk1JRjBRT25MTFZQNEptdkhPRWJYdnR1djU3UkxtbmhsLXZYaEpiY1RJdFNn?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON) - The Globe and Mail","headline":"Analysts Are Bullish on These Healthcare Stocks: Entrada Therapeutics Inc (TRDA), CG Oncology, Inc. (CGON)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01SEIwTGJrdUdxZ21NN2pfcF9ScGNqUzl5d2ZuaUV6N01CSjVkZmQ2V043YTVVRklSeEJZOUpLY3FoR2xZUFJuMktJbFdWTFBLU1hydXhYc3poOHJ1cGtKWWlmZlZrY2RUeDRrd2V3?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA) - Stock Titan","headline":"If You Invested $1,000 in Entrada Therapeutics, Inc. (TRDA)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOSFY0cFZQQlNWMzlIb1FRcXNQcEM5RzJEalZNUGlrRlVhcWExQVRzbVRXeVNKN2Z1ZV8xZWFLeXJwd1hnM0VsS3hiUUl6ZF9uS3ZjaGZFMjA5cXhfeTN5cTRtTTlwbzJ0LWRZU05pVl90U016N3hUdnFKb1F5b3c4UnJ3bnJnWERxTllrVzRfNnREU0JtRjJOWThQTzM2bXFMSVhLRFdPNl9sNWsyal9kbEpjVU9FOVNaOHBWSllCYnQtdk43VzlMSjdDM3h1aUtpYlc0dHBWRWxsNWc?oc=5","date":"2026-02-16","type":"pipeline","source":"Columbus CEO","summary":"Scioto AgriTech Is Developing Biologic Agents to Improve Crop Health - Columbus CEO","headline":"Scioto AgriTech Is Developing Biologic Agents to Improve Crop Health","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxQbHNGdHg5QWNheHRlaXlXNWl4MzE2cndjbnBPSE50RUQ3Z1l6dW9GdnpScHdqRWt6QTZCLUlIUl92OEE5MXd3N0ZlRWdZaUpNOE9QdjVGZzJxNXhGZjc0b1V6VmdhVW8yT0U4cW9WT2o5d2t4RkRsdXdyR0JEVWJjd1dvdUdQT0hJcVhJbVBiMVBteUZhNkFVZnNPWm8yUmk2a2hFeDVLUzZyMzQ5MVBrNE9PLXM2MWZtMUZMaFY1c3lTbEstcjlVckpmcTJidWI3UU5pNTlweUw1TGZ6dFJONU5CQk8tVWhKTDZJUV9CaTdsMS03LWdSLUJiSU94T3piYk9MbmFPNi1YZDg?oc=5","date":"2026-01-09","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-09","type":"pipeline","source":"simplywall.st","summary":"Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st","headline":"Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNblRZbkVlYU9HV1lkZzIwWG5zeGl6OHp3bmVialMwbHpMNWQzRDRabldkZFpGMFdiV09DbDBmNXBRQ21QQXd0cEZrSWRYT3NZMzJYb0gtN0tEZFlUeGZjbXU4ZzZjR1BXZDBtQWgxd3dyN3hfendwQWR0aTJDaEQ2Vi12TjJrZTRyTTRnck5oaGFFM0N3U3VXcXRR?oc=5","date":"2025-04-30","type":"regulatory","source":"Fierce Biotech","summary":"Entrada lays off 20% of staff weeks after having FDA hold lifted - Fierce Biotech","headline":"Entrada lays off 20% of staff weeks after having FDA hold lifted","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNemRDVjY0cU4wdjFrT2EzRS03eDdQd0RBazlsVGRoM3JhODFnay1IRHlGV0xOYWhyTF93d0I2ZDJZNUM0ekdxNTZiYktEcDJVUlVlZDBnRDRTLU53MEtoeUxJV3ZVNTViY0pVNUNVb1UwWnBnRmZ0SDU4RXJpVjB1cWxzNU84bWRkMW01NThZdkxnZXlaWGpqeVJlamtEd0JwVjNPVFBBZGRHT3pvdDJxSFVtd2M4cUdVVDkydk1fWm5laU01VTY4c2VB?oc=5","date":"2025-04-15","type":"pipeline","source":"Healio","summary":"Gene therapy improves functional outcomes for boys with Duchenne muscular dystrophy - Healio","headline":"Gene therapy improves functional outcomes for boys with Duchenne muscular dystrophy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxQaHAweXUwLXpfTXF1RFdVaUJ1M196ajJ6OEV4eVRyNXJmdXJMbldMU3dod3k2b0h1TUJ6VW9YUERxQXBEMno0WW9faVc0Tl9UaWMwU1hNZ2NSRVNwVk82NVpGckRGV2tXRGdGcVlRUFQ1dlFxYnJqaDM5X19xXzVhTWJ0aTY3WUhlZ1ptVmJYTThIYUh1VTJEcEQ1NE5oUlhmN1dBdjRfMTVQUm5OdUFka0JIZ243X2V1M0FwenVrWU1XQ3dlR3IzMGF3V0JDQi1LbGZ4eFFkUnhBSnd0QTJUcENrelhkczR3bzlqWmJTX3VpM3lCaFlUaEVVMnhERWdRbTFScFlSbHdYWnRsX3FYbEdUTQ?oc=5","date":"2024-11-27","type":"trial","source":"PR Newswire","summary":"Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | DelveInsight - PR Newswire","headline":"Myotonic Dystrophy Clinical Trial Pipeline Boom as Over 20 Companies Leading the Charge in Research and Development | De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOS1g4YjNQYy0tNkF6aHVjcG1lYno1dzliV2gxN21jMWswdzRkQ0JKQVFleXBaU1RJZkRoTUdtd3kzclZIYmxER0NaVVptZC1heC05UVRTYTNsMHFQVVI4OFJWX0FsUjJMUTUweHVJc256czRIeHlFOEtNWTRKM016c0VtVzQxdw?oc=5","date":"2022-12-09","type":"deal","source":"Pharmaceutical Technology","summary":"Vertex and Entrada partner for EEV therapeutics development - Pharmaceutical Technology","headline":"Vertex and Entrada partner for EEV therapeutics development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQU3RtR1FuLXpaWTNjZmNLeGRTS0FkTE1HLUNGMGZ6OWp3bmUtT0hvekJEZEtZRnFDbkNuVUN4ZThwMERJZ3lGQ21TOTJtRUNhSDY1T3BPQjBkeHBQZnJpMERyaXB6VzdnOTAzZ2s5TDNESXVRTFVQdmh0Wnh0MjRzalltV0ZmdGliZWRMenlQWHI3U0E?oc=5","date":"2022-12-08","type":"deal","source":"BioSpace","summary":"Vertex Pursues Myotonic Dystrophy with $250M Entrada Deal - BioSpace","headline":"Vertex Pursues Myotonic Dystrophy with $250M Entrada Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQMzNONUtLaG9ValBXcEVudm11X0ZlSXVqc1R1ZWNHUGpRc053RnA1S1lEamZrZWJNNEJrclMzN0RjNmo0LXZ5Yi1oYmxvdk5Va2w3RnI4Zk5nTmxXVmVmVVN5c0pYcTNqWGFnRlBUaU5SOW5LTG4tWFllZTZDSlhkbkQ1cjJNZkhyV3VuQ2FtX3VhZw?oc=5","date":"2022-12-08","type":"pipeline","source":"BioPharma Dive","summary":"Vertex invests in a rare disease drug and its developer - BioPharma Dive","headline":"Vertex invests in a rare disease drug and its developer","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}